Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity
Zhi‐Fu Tao(AbbVie (United States)), Andrew J. Souers(AbbVie (United States)), Paul Nimmer(Abbott Fund), Chris Tse(AbbVie (United States)), Sha Jin(AbbVie (United States)), Kurt Deshayes(Unknown), Russell A. Judge(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Hans E. Purkey, Darren C. Phillips(AbbVie (United States)), Xiao Yu(Huazhong Agricultural University), Lisa Hasvold(AbbVie (United States)), Nathaniel D. Catron(AbbVie (United States)), Chang H. Park(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), Keith G. Watson(The University of Melbourne), Wayne J. Fairbrother(Gene Therapy Laboratory), Xilu Wang(AbbVie (United States)), Peter M. Colman(The University of Melbourne), Kerry Zobel, Anatol Oleksijew(Abbott Fund), Peter E. Czabotar(The University of Melbourne), Brad E. Sleebs(The University of Melbourne), John A. Flygare, S.G. Hymowitz, Andrew M. Petros(Abbott Fund), Michael F. T. Koehler, Guillaume Lessène(The University of Melbourne), Brian J. Smith(The University of Melbourne), Joel D. Leverson(AbbVie (United States)), Le Wang(Rutgers, The State University of New Jersey), Jun Chen(Jilin University), Haichao Zhang(Abbott Fund), Stephen K. Tahir(Abbott Fund), Steven W. Elmore(AbbVie (United States)), John Xue(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Peter Kovar(AbbVie (United States)), Michael J. Mitten(Abbott Fund), Chudi Ndubaku
Cited by 331
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k